BIOFRONTERA INC (BFRI)

US09077D2099 - Common Stock

1.01  +0.03 (+3.22%)

After market: 1.08 +0.07 (+6.93%)

News Image
10 hours ago - Biofrontera Inc.

Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market

Biofrontera started commercial distribution of the RhodoLED XL in June 2024 and has seen rapid uptake in the US market since launch.The RhodoLED XL is...

News Image
a month ago - Biofrontera Inc.

Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note

WOBURN, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company...

News Image
a month ago - Biofrontera Inc.

Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update

 ●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not...

News Image
2 months ago - Biofrontera Inc.

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant...

News Image
2 months ago - Biofrontera Inc.

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of...

News Image
3 months ago - Biofrontera Inc.

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL...

News Image
4 months ago - InvestorPlace

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

BFRI stock results show that Biofrontera beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

News Image
4 months ago - BusinessInsider

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the second quarter of 2024....

News Image
4 months ago - Biofrontera Inc.

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the

News Image
6 months ago - Biofrontera Inc.

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of...

News Image
7 months ago - InvestorPlace

BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024

BFRI stock results show that Biofrontera missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Image
7 months ago - BusinessInsider

BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the first quarter of 2024.B...

News Image
9 months ago - InvestorPlace

3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million

If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.

News Image
9 months ago - InvestorPlace

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023

BFRI stock results show that Biofrontera beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

News Image
9 months ago - BusinessInsider

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the fourth quarter of 2023....